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Objective: The purpose of this study was to re-evaluate post-remission therapy outcomes
after first remission according to years of patient enrolment in patients with core binding
factor acute myeloid leukaemia.
Methods: We conducted a retrospective study on 138 patients aged less than 60 years diag-
nosed with core binding factor acute myeloid leukaemia between 1994 and 2006, comparing
allogeneic stem cell transplantation and high-dose cytarabine chemotherapy as post-remis-
sion treatment options after the first remission.
Results: The 5-year probabilities of disease-free survival and overall survival were not differ-
ent between allogeneic stem cell transplantation and high-dose cytarabine groups. However,
3-year probabilities of disease-free survival (86.7% vs. 67.0%) and overall survival (90.0% vs.
67.3%) showed a trend towards improvement in the allogeneic stem cell transplantation group
compared with the high-dose cytarabine group in cohort after 2003 (2003–2006), whereas
outcomes were not different in cohort before 2003 (1994–2002). Especially, 3-year probabil-
ities of disease-free survival (95.2% vs. 59.3%, P ¼ 0.008) and overall survival (95.2% vs.
59.6%, P ¼ 0.032) of allogeneic stem cell transplantation group were significantly better than
high-dose cytarabine group in cohort after 2003 of acute myeloid leukaemia patients with
t(8;21). The relative risk of overall survival with allogeneic stem cell transplantation, compared
with high-dose cytarabine chemotherapy, was significantly improved in the cohort after 2003
(0.33; 95% CI, 0.07–1.48) when compared with that before 2003 (1.92; 95% CI, 0.77–4.82).
In multivariate analysis in cohort after 2003, allogeneic stem cell transplantation as post-
remission therapy was associated with better disease-free survival.
Conclusions: Allogeneic stem cell transplantation is currently the more effective post-remis-
sion therapy than it was prior to 2003 for core binding factor acute myeloid leukaemia achiev-
ing first remission. On the contrary to previous findings, allogeneic stem cell transplantation
provides significantly improved outcomes than high-dose cytarabine chemotherapy in acute
myeloid leukaemia with t(8;21).
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Cytogenetically, core binding factor (CBF) acute myeloid leu-
kemia (AML) is deﬁned by the presence of t(8;21)(q22;q22)
or inv(16)(p13q22)/t(16;16)(p13;q22). CBF AML is identiﬁed
in 13–15% adult patients with de novo AML (1). In view of
the involvement of CBF subunits at the molecular level and
positive response to treatment, CBF AML is associated with
relatively favourable prognosis, compared to that of patients
displaying normal or adverse karyotypes.
AML patients with favourable cytogenetics display a more
than 80% chance of attaining complete remission (CR) and
improved disease-free survival (DFS), compared with the
other cytogenetic groups (2,3). Several chemotherapeutic
strategies have been reported, among which high-dose cytar-
abine (HDAC) is generally the most effective option for suc-
cessful post-remission therapy (4). The overall survival (OS)
rate at 5 years in patients with favourable cytogenetics sub-
jected to intensive HDAC post-remission therapy exceeds
50% (5–7). However, even in CBF AML patients achieving
CR, 40–50% relapse has been observed, and the probability
of long-term survival has not been still satisﬁed. Marcucci
et al. reported that consolidation therapy with multicourse
HDAC in younger patients decreased the relapse rate (RR)
(7); however, this did not translate into more favourable sur-
vival for CBF AML patients.
Although patients with favourable cytogenetics receiving
autologous stem cell transplantation (autoSCT) displayed
markedly lower RR after four cycles of chemotherapy than
those not given such therapy, a high procedural mortality rate
was found in adults subjected to autoSCT, resulting in no
differences in OS (5). Furthermore, none of the randomized
studies disclosed an advantage of allogeneic SCT (alloSCT) in
this group of patients, given the relatively high treatment-
related death (TRD) rate (8–12). However, the time of CBF
AML patient enrolment in most reports handling post-
remission therapy outcomes were earlier than 2003 (8–12),
and no relevant studies in patients enrolling after 2003 have
appeared to date. Over the last decade, the outcomes of
alloSCT in haematologic malignancies have improved as a
result of substantially reduced treatment-related mortality fol-
lowing modiﬁcation of transplant procedures, including graft
versus host disease (GVHD) prophylaxis and conditioning
regimens (13). Therefore, re-analysis of recent outcomes using
alloSCT and HDAC as post-remission therapy for CBF AML
patients is required. Here, we report the results of a nation-
wide retrospective analysis on CBF AML patients aged less
than 60 years, comparing alloSCT and HDAC chemotherapy
as post-remission treatment options after the ﬁrst remission.
METHODS
PATIENTS AND DATA COLLECTION
Data were obtained from questionnaires distributed to each
hospital. A questionnaire containing a set of data including
demographic, diagnostic, clinical and laboratory data, cyto-
genetics, presence of extramedullary involvement,
French-American-British (FAB) morphological classiﬁ-
cation, type of post-remission and salvage therapy, transplan-
tation data including conditioning regimen, acute GVHD
prophylaxis and stem cell sources, and outcomes was
ﬁlled out for each patient. Inclusion criteria were as follows:
(i) presence of t(8;21)(q22;q22) or inv(16)(p13q22)/
t(16;16)(p13;q22) on standard karyotypic analysis; (ii) age
16–59 years; (iii) achieving ﬁrst CR after remission-
induction chemotherapy; and (iv) availability of clinical
data. All consecutive patients who fulﬁlled the inclusion cri-
teria were included. Among the patients subjected to
alloSCT as post-remission therapy (alloSCT group), patients
undergoing transplantation without consolidation chemother-
apy, and received intermediate-dose cytarabine or HDAC as
consolidation chemotherapy were included. Within-patients
received HDAC chemotherapy alone as post-remission
therapy (HDAC group), patients receiving more than two
cycles of HDAC consolidation chemotherapy were included.
TREATMENT PROTOCOLS
Among HDAC group, those treated with a minimum of three
cycles of HDAC (3 g/m2 intravenously every 12 h, days 1, 3
and 5, or 3 g/m2 intravenously every 12 h for 4 days) were
selected, and included regimens containing mitoxantrone,
etoposide or idarubicin/daunorubicin. Within the alloSCT
group, 29/60 (48.3%) patients received HDAC-containing
consolidation chemotherapy before transplantation.
Conditioning regimen, prophylaxis and treatment of
GVHD were administered according to the speciﬁc protocols
of each transplant centre. Out of the 60 alloSCT patients, 38
were prepared using a combination of busulfan (3.2 mg/kg/
day intravenously on four consecutive days) and cyclopho-
sphamide (60 mg/kg/day on two consecutive days) with or
without etoposide (30 mg/kg/day for one day), whereas 10
received total body irradiation of 12 Gy with 60 mg/kg/day
cyclophosphamide on two consecutive days. Another 10
patients received a combination of busulfan (3.2 mg/kg/day
intravenously on four consecutive days) and ﬂudarabine
(30 mg/m2 intravenously on six consecutive days). One
patient was administered ﬂudarabine with melphalan, and
one patient received another regimen. Cyclosporine plus
methotrexate (54 patients), FK-506 plus methotrexate (three
patients) and methotrexate alone (three patients) were
employed as GVHD prophylaxis.
STATISTICAL ANALYSIS
The deﬁnition of CR followed the recommended criteria
(14). To evaluate the differences between patients subjected
to alloSCT and HDAC groups after achieving CR, categori-
cal variables were compared using the x2 test, and continu-
ous variables were evaluated with the Mann–Whitney
U test. Cumulative incidence was used for TRD and RR.





















When comparing outcomes of alloSCT and HDAC
groups, differences in time to post-remission treatment
including SCT is potential sources of bias and require appro-
priate adjustments. To address this potential bias, semi-
landmark analysis was used for analysing DFS and OS of
both groups as previously described (15–17). Brieﬂy, in
patients of alloSCT group, the day of the stem cells infusion
from the ﬁrst remission was deﬁned as the landmark day; in
patients of HDAC group, 5 months from the ﬁrst remission,
which was the median time of the day of the stem cells
Table 1. Characteristics of patients according to post-remission therapy
Characteristics All patients (n ¼ 138) Allogeneic SCT (n ¼ 60) Chemotherapy (n ¼ 78) P-value
Median Dx day, year (range) 2003 (1994–2006) 2003 (1996–2005) 2003 (1994–2006) 0.351
Median age, years (range) 37 (14–59) 35.5 (15–59) 41 (14–59) 0.122
Sex, male/female (%) 75/63 (54.3/45.7) 41/19 (68.3/31.7) 34/44 (43.6/56.4) 0.004
Median WBC, 109/l (range) 9.8 (0.5–393.0) 10.4 (0.7–338.8) 9.1 (0.5–393.0) 0.234
Median Hb, g/dl (range) 7.9 (2.3–14.7) 7.5 (2.3–13.4) 8.2 (2.4–14.7) 0.376
Median PLT, 109/l (range) 36 (6–593) 33 (6–532) 39 (7–593) 0.650
Median PB blast, % (range) 41 (0–90) 38 (1–89) 42 (0–90) 0.835
Median marrow blast, % (range) 52.7 (8.8–95.2) 52.3 (8.8–93.0) 52.8 (12.5–95.2) 0.699
Median LDH, IL/U (range) 845 (207–23650) 968.5 (267–15690) 702 (207–23650) 0.034
FAB class (%)
M1 5 (3.6) 3 (5) 2 (2.6) 0.167
M2 103 (74.6) 40 (66.7) 63 (80.8)
M4 30 (21.7) 17 (28.3) 13 (16.7)
Core binding factor
Including t(8;21) 108 (78.3) 43 (71.7) 65 (83.3) 0.100
Including inv(16) 30 (21.7) 17 (28.3) 13 (16.7)
Del (9)(q22) abnormality (%)
Yes 10 (7.2) 3 (5.0) 7 (9.0) 0.356
No 122 (88.4) 55 (91.7) 67 (85.9)
n.a. 6 (4.3) 2 (3.3) 4 (5.1)
Sex chromosome loss
Yes 67 (48.6) 33 (55.0) 34 (43.6) 0.212
No 65 (47.1) 25 (41.7) 40 (51.3)
n.a. 6 (4.3) 2 (3.3) 4 (5.1)
Complex karyotype
Yes 24 (17.4) 12 (20.0) 12 (15.4) 0.508
No 108 (78.3) 46 (76.7) 62 (79.5)
n.a. 6 (4.3) 2 (3.3) 4 (5.1)
Initial response (%)
CR 119 (86.2) 52 (86.7) 67 (85.9) 0.897
NR 19 (13.8) 8 (13.3) 11 (14.1)
Courses to CR (%)
1 cycle 119 (86.2) 52 (86.7) 67 (85.9) 0.897
2 cycles 18 (13.0) 8 (13.3) 10 (12.8)
3 cycles 1 (0.7) 0 1 (1.3)
Median duration of post-remission treatment, months (range) n.a. n.a. 8 (5–14) —
Median time from ﬁrst CR to transplant, months (range) n.a. 5 (2–13) n.a. —
SCT, stem cell transplantation; WBC, white blood cell; Hb, haemoglobin; PLT, platelet; FAB, French-American-British; LDH, lactate dehydrogenase; CR,
complete remission; NR, no remission; Dx, diagnosis; PB, peripheral blood; n.a., not available.





















infusion from the ﬁrst remission was deﬁned as the landmark
day. DFS was estimated from the landmark day until the
date of AML relapse or death from any cause. OS was
measured from the landmark day until death from any cause
(4). DFS and OS were calculated according to the Kaplan–
Meier method, and patients receiving alloSCT and HDAC
alone were compared with the log-rank test. Univariate and
multivariate survival analyses were carried out using the Cox
proportional hazards model.
RESULTS
PATIENTS AND DISEASE CHARACTERISTICS
The study patients and disease characteristics are summar-
ized in Table 1. In total, 322 AML patients from 18 insti-
tutions in Korea aged 16–59 years with either
t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22), who
achieved CR after remission-induction chemotherapy
between January 1994 and March 2006 were reviewed retro-
spectively. Among the 322 CBF AML patients, 184 were
considered ineligible. Of these, 133 patients were categor-
ized as such based on receiving less than three cycles of con-
solidation chemotherapy and 20 who received low-dose or
intermediate-dose cytarabine consolidation chemotherapy in
HDAC group, and 31 who underwent autoSCT. Overall, 138
AML patients undergoing alloSCT and more than two cycles
of HDAC consolidation chemotherapy alone in the ﬁrst CR
were analysed. Of the 60 patients who underwent alloSCT,
52 underwent SCT with human leukocyte antigen
(HLA)-identical sibling donor and 8 with HLA-identical
unrelated donor.
A relatively higher number of female patients were
included in HDAC group (male:female ¼ 1:1.29) compared
with alloSCT group (male:female ¼ 1:0.46) (P ¼ 0.004).
Lactate dehydrogenase (LDH) levels were higher in alloSCT
group than HDAC group (P ¼ 0.034). Thirty-two patients
(53.3%) of alloSCT group and 36 patients (46.2%) of HDAC
group had initial high WBC count, and it did not show any
statistical signiﬁcance. Other variables, including age, initial
platelet counts, haemoglobin, peripheral and bone marrow
(BM) blast counts, FAB classiﬁcation, additional cytogenetic
abnormalities, response to remission-induction chemotherapy
and number of courses to achieve CR were not signiﬁcantly
different between the two groups.
OUTCOMES ACCORDING TO POST-REMISSION THERAPY
The median follow-up duration was 46 months (range: 10–
151 months). In total, 35 of the 138 patients died, and
follow-up loss was reported for nine patients. Among the
138 patients with CR, the probabilities of DFS and OS at
5 years were 69.0+ 4.0% and 77.9+ 3.8%, respectively.
The 5-year probabilities of DFS and OS did not have any
difference between alloSCT and HDAC groups (Fig. 1).
COMPARISON OF DFS AND OS ACCORDING TO YEARS OF PATIENT
ENROLMENT
As the median year value of patient diagnosis was 2003, out-
comes were analysed in patient cohorts enrolled before 2003
(1994–2002) and after 2003 (2003–2006). The median
follow-up duration in the cohort before 2003 was 72 months
(range, 48–151 months), and 25.5 months after 2003 (range,
10–48 months). The 3-year probabilities of DFS and OS
were not signiﬁcantly different when the alloSCT and
HDAC groups before 2003 were compared (Fig. 2). There
was trend towards better 3-year probabilities of DFS (86.7+
6.2% vs. 67.0+ 7.7%) and OS (90.0+ 5.5% vs. 67.3+
8.8%) in the alloSCT group after 2003 compared with those
of the HDAC group, but this was not statistically signiﬁcant.
We analysed the outcomes of each post-remission therapy
according to the treatment before and after 2003. DFS and
OS of the HDAC group were comparable, both cohorts
before and after 2003. On the other hand, 3-year DFS and
Figure 1. Five-year probabilities of disease-free survival (A) and overall
survival (B) according to post-remission therapy.





















OS rates of the alloSCT group in the cohort after 2003 were
considerably improved compared with those before 2003
(86.7+ 6.2% vs. 60.0+ 8.9%, P ¼ 0.031; 90.0+ 5.5% vs.
59.8+ 9.0%, P ¼ 0.055) (Fig. 3).
We also analysed outcomes of 108 AML patients with
t(8;21)(q22;q22) according to post-remission therapy or
cohorts before and after 2003. Three-year probabilities of
DFS (95.2+ 4.6% vs. 59.3+ 8.9%, P ¼ 0.008) and OS
(95.2+ 4.6% vs. 59.6+ 10.3%, P ¼ 0.032) of alloSCT
group in the cohort after 2003 were higher than HDAC
group, while those were not different between two groups in
the cohort before 2003 (Fig. 4). Three-year probabilities of
DFS (95.2+ 4.6% vs. 54.5+ 10.6%, P ¼ 0.003) and OS
(95.2+ 4.6% vs. 54.5+ 10.6%, P ¼ 0.012) of the cohort
after 2003 in alloSCT group were higher than the cohort
before 2003, while those between the cohort before 2003
and after 2003 were not different in HDAC group (Fig. 5).
The outcomes of AML patients with inv(16) could not be
analysed because small number of patients were included in
this group.
The cumulative incidence of TRD between the cohorts
before and after 2003 in HADC group was similar, however,
it was decreased from 40.2% before 2003 to 10.0% after
2003 in alloSCT group. The cumulative incidence of RR
between the two groups before 2003 was not different, but
decreased more in the alloSCT group than HDAC group
after 2003 (6.7 vs. 29.9%, P ¼ 0.072) (Table 2).
Univariate and multivariate analyses for DFS and OS were
performed on cohorts divided according to dates before and
after 2003. In univariate analysis, no variables inﬂuenced
DFS or OS in the cohort before 2003, and only alloSCT was
associated with favourable DFS (P ¼ 0.029) in the cohort
after 2003. In multivariate analysis, age at diagnosis signiﬁ-
cantly inﬂuenced DFS and OS in the cohort before 2003, and
alloSCT as post-remission therapy signiﬁcantly improved
DFS in the cohort after 2003 (Table 3). In the cohort before
2003, relative risk of DFS and OS were 1.46 (95% CI, 0.63–
3.40) and 1.92 (95% CI, 0.77–4.82), respectively, for
alloSCT, compared with post-remission HDAC chemother-
apy. Interestingly, in cohort after 2003, the relative risks of
DFS and OS were signiﬁcantly decreased (0.25; 95% CI,
0.07–0.94 and 0.33; 95% CI, 0.07–1.48) in the alloSCT
group, respectively, compared with the HDAC group.
ANALYSIS OF ALLOSCT
We deﬁned the characteristics of alloSCT in cohorts before
and after 2003 (Table 4). Among these, higher levels of sex
Figure 2. Three-year probabilities of disease-free survival and overall survival according to post-remission therapy in cohorts before and after 2003. Graphs
show 3-year probabilities of (A) disease-free survival and (B) overall survival in cohorts before 2003, and 3-year probabilities of (C) disease-free survival and
(D) overall survival in cohorts after 2003. AlloSCT, allogeneic stem cell transplantation; CTx, chemotherapy.





















Figure 4. Three-year probabilities of disease-free survival and overall survival according to post-remission therapy in cohorts before and after 2003 of AML
patients with t(8;21)(q22;q22). Graphs show 3-year probabilities of (A) disease-free survival and (B) overall survival in cohorts before 2003, and 3-year prob-
abilities of (C) disease-free survival and (D) overall survival in cohorts after 2003. AlloSCT, allogeneic stem cell transplantation; CTx, chemotherapy.
Figure 3. Three-year probabilities of disease-free survival and overall survival according to cohorts before and after 2003 in each post-remission therapy.
Graphs show 3-year probabilities of disease-free survival (A) and overall survival (B) of HDAC group, and disease-free survival (C) and overall survival (D)
of alloSCT group.





















chromosome loss were detected in cohort before 2003, com-
pared with those after 2003, in cytogenetic analyses.
Matched unrelated donor SCT was more frequently per-
formed in cohort after 2003 compared to cohort before 2003
(P ¼ 0.044). Busulfan/cyclophosphamide (BuCy) and total
body irradiation/cyclophosphamide (TBICy)-based therapies
were used as conditioning regimens in cohort before 2003.
On the contrary, other conditioning regimens, such as ﬂudara-
bine/busulfan (FluBu), were introduced after 2003 (P ¼
0.009). Most patients assigned to cohort before 2003 received
BM as the source of cells for SCT, whereas use of peripheral
blood (PB) increased in cohort after 2003 (P ¼ 0.006).
DISCUSSION
In the current study, DFS and OS were not signiﬁcantly
different between alloSCT and HDAC groups of CBF AML
Figure 5. Three-year probabilities of disease-free survival and overall survival of AML patients with t(8;21)(q22;q22) according to cohorts before and after
2003 in each post-remission therapy. Graphs show 3-year probabilities of disease-free survival (A) and overall survival (B) of HDAC group, and disease-free
survival (C) and overall survival (D) of alloSCT group.
Table 2. Cumulative incidence of treatment-related death and relapse rate according to enrolment periods
Period n Treatment-related death Relapse rate
% 95% CI P % 95% CI P
Before 2003 (n ¼ 64)
Chemotherapy 34 32.2 19.3–53.9 0.658 45.3 31.1–66.0 0.199
AlloSCT 30 40.2 25.9–62.3 23.3 12.2–44.6
After 2003 (n ¼ 74)
Chemotherapy 44 32.7 19.3–55.4 0.197 29.9 18.5–48.5 0.197
AlloSCT 30 10.0 3.4–29.3 6.7 1.8–25.4
CI, conﬁdence interval; AlloSCT, allogeneic stem cell transplantation.





















patients achieving ﬁrst CR as previous data. However, there
was a trend towards higher DFS and OS with alloSCT group
(86.7 and 90.0%) vs. HDAC group (67.0 and 67.3%) in
cohort after 2003, whereas no differences were observed
between the two groups in cohorts before 2003. In particular,
the relative risk of DFS and OS of alloSCT group in cohort
after 2003 reduced signiﬁcantly to 0.25 and 0.33 compared
with HDAC chemotherapy as post-remission therapy, while
the relative risk of survival in alloSCT group was higher
than HDAC chemotherapy group in cohort before 2003.
These results suggest that in contrast to outcomes obtained
with cohort before 2003, which showed similar data as pre-
vious papers (8–12), alloSCT was useful in AML patients
with CBF achieving ﬁrst CR in cohort after 2003. This trans-
lated as a lower incidence of RR in the alloSCT group com-
pared with the HDAC group in cohort after 2003 and
reduced TRD and RR of alloSCT in cohort after 2003 com-
pared with in those before 2003. It is possible that HDAC
consolidation chemotherapy prior to alloSCT would affect
the TRD in cohort between before and after 2003 in alloSCT
group. Contrary to our expectation, HDAC chemotherapy
was introduced more in cohort after 2003 than before
2003 in alloSCT group [20/30 (66.7%) vs. 9/30 (30.0%),
P ¼ 0.004].
Interestingly, in the current study, the 3-year survival
rates of alloSCT group in cohort after 2003 were signiﬁ-
cantly higher than those before 2003, whereas no differ-
ences in HDAC group were evident before and after 2003.
Patients subjected to alloSCT after 2003 were given more
PB as a source of SCT cells, and introduced FluBu che-
motherapy as the conditioning regimen compared with the
cohort before 2003. A randomized multicentre trial of allo-
grafting for myeloid malignancies revealed that patients
randomized to receive PB displayed signiﬁcantly better OS
when compared with those randomized to receive BM, and
this beneﬁt was because of lower non-relapse mortality
(18). In early-stage disease, including ﬁrst CR of AML,
the PB SCT source was also associated with lower RR
(19). Our study revealed lower RR in alloSCT group in
cohorts after 2003, which might be attributed to the use of
more PB SCT, compared with those before 2003. The
BuCy regimen has been employed most commonly for
conditioning in alloSCT. However, high treatment-related
mortality caused by the additive cytotoxicity of these two
alkylators is still a problem (20,21). Russell and co-
workers suggested that the FluBu combination is a well-
tolerated and safe low-toxicity myeloablative conditioning
treatment (22,23). The outcomes of AML/MDS patients
treated with FluBu were signiﬁcantly better than those
given BuCy (24). The possibility that better outcomes of
alloSCT group in cohort after 2003 can be attributed to
both higher levels of PB SCT and introduction of the
FluBu conditioning regimen cannot be ruled out.
CBF AML patients are commonly treated with conven-
tional chemotherapy, and alloSCT is reserved for relapse
cases only. However, in the Cancer and Leukemia Group B
study, RR was relatively high, reported as 53%, and long-
term survival rates of CBF AML patients are still disappoint-
ing (5-year OS rate of 50%) (7). Furthermore, survival of
Table 3. Multivariate analysis of disease-free survival and overall survival
in AML with core binding factor according to years of patient enrolment
Parameter Disease-free survival Overall survival
RR 95% CI P RR 95% CI P
Before 2003 (n ¼ 64)
Sex
Male 1 0.24–1.47 0.261 1 0.16–1.35 0.157
Female 0.60 0.46
Age (years)
35 1 0.16–1.00 0.049 1 0.11–0.81 0.018
,35 0.39 0.29
WBC (109/l)
,10 1 0.23–1.40 0.219 1 0.17–1.17 0.102
10 0.57 0.45
LDH
Abnormal 1 0.55–7.02 0.297 1 0.67–10.81 0.164
Normal 1.97 2.69
Initial response
NR 1 0.34–3.43 0.889 1 0.23–2.51 0.654
CR 1.09 0.76
Post-remission therapy
HDAC 1 0.63–3.40 0.375 1 0.63–3.40 0.375
AlloSCT 1.46 1.92
After 2003 (n ¼ 74)
Sex
Male 1 0.35–2.83 0.991 1 0.24–2.91 0.785
Female 0.99 0.84
Age (years)
35 1 0.18–1.94 0.384 1 0.16–2.36 0.483
,35 0.59 0.62
WBC (109/l)
,10 1 0.54–4.41 0.419 1 0.31–4.06 0.853
10 1.54 1.13
LDH
Abnormal 1 0.13–2.00 0.331 1 0.16–3.30 0.669
Normal 0.51 0.72
Initial response
NR 1 0.06–1.17 0.081 1 0.09–2.71 0.412
CR 0.27 0.49
Post-remission therapy
HDAC 1 0.07–0.94 0.040 1 0.07–1.48 0.148
AlloSCT 0.25 0.33





















patients with CBF after the ﬁrst relapse was poor. In particu-
lar, 5-year post-relapse survival of patients with t(8;21) was
only 14%, compared to 34% of patients with inv(16). In a
meta-analysis of several German AML trials, the CR rate
and survival after re-induction therapy were signiﬁcantly
lower in patients with t(8;21) compared to those with
inv(16), whose long-term survival was less than 50% (10).
In the subset analysis of current study, the DFS and OS of
alloSCT group in AML patients with t(8;21) in cohort after
2003 were dramatically increased compared with the HDAC
group that showed statistically signiﬁcant, while survival
between both the groups were not different in cohort before
2003. Therefore, at least, alloSCT using recently improved
transplantation methods might be beneﬁcial in AML patients
with t(8;21) who achieved ﬁrst CR if they have
HLA-matched sibling donor.
The main limitation of this study is not prospective. Since
the results were analyzed retrospectively, randomization
depending on donor availability could not be performed, and
were therefore potentially subject to selection bias.
Nevertheless, the data effectively conﬁrm that more recent
outcomes of the alloSCT group in CBF AML patients,
especially with t(8;21), are better than those of the HDAC
group, whereas no differences between the two groups were
observed previously, even when patients were not assigned
on the bias of donor availability.
To our knowledge, this is the ﬁrst report showing that
recent outcomes of alloSCT as post-remission therapy are
Table 4. Characteristics of patients subjected to allogeneic stem cell transplantation according to years of patient enrolment
Characteristics Before 2003 (n ¼ 30) After 2003 (n ¼ 30) P-value
Sex, male/female (%) 21/9 (70/30) 20/10 (66.7/33.3) 0.781
Median age, years (range) 35.5 (15–48) 35.5 (17–60) 0.258
Core binding factor, t(8;21)/inv(16) (%) 22/8 (73.3/26.7) 21/9 (70.0/30.0) 0.774
Median WBC (109/l) (range) 17.7 (0.7–338.8) 9.7 (1.2–100.8) 0.110
LDH, IL/U (%)
Normal/abnormal/n.a. 2/25/3 (6.7/83.3/10.0) 5/24/1 (16.7/80.0/3.3) 0.928
Del (9)(q22) abnormality (%)
Yes/no/n.a. 2/27/1 (6.7/90.0/3.3) 1/28/1 (3.3/93.3/3.3) 0.553
Sex chromosome loss (%)
Yes/no/n.a. 20/9/1 (66.7/30.0/3.3) 13/16/1 (43.3/53.3/3.3) 0.063
Complex karyotype (%)
Yes/no/n.a. 5/24/1 (16.7/80.0/16.7) 7/22/1 (23.3/73.3/3.3) 0.517
Extramedullary involvement (%)
Yes/no 1/29 (3.3/96.7) 4/26 (13.3/86.7) 0.161
Donor type (%)
Matched sibling/unrelated 28/2 (93.3/6.7) 24/6 (80.0/20.0) 0.044
Stem cell source (%)
BM/PB/n.a. 22/4/4 (73.3/13.3/13.3) 12/13/5 (40.0/43.3/16.7) 0.006
GVHD prophylaxis (%)
CsA þMTX 29 (96.7) 25 (83.3) 0.098
FK-506 þMTX 0 3 (10.0)
MTX alone 1 (3.3) 0
Corticosteroid 0 2 (6.7)
Conditioning regimen (%)
BuCy based 22 (73.4) 16 (53.3) 0.009
TBICy based 7 (23.4) 3 (10.0)
FluMel 1 (3.3) 0
FluBu 0 10 (33.3)
Other 0 1 (3.3)
WBC, white blood cell; Hb, haemoglobin; PLT, platelet; FAB, French-American-British; LDH, lactate dehydrogenase; BM, bone marrow; PB, peripheral
blood; n.a., not available; GVHD, graft-versus-host disease; CsA, cyclosporine; MTX, methotrexate; BuCy, busulfan plus cyclophosphamide; TBICy, total
body irradiation plus cyclophosphamide; FluMel, ﬂudarabine plus melphalan; FluBu, ﬂudarabine plus busulfan.





















improved compared with HDAC chemotherapy alone follow-
ing ﬁrst remission of CBF AML patients, and especially
those with t(8;21).
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